Mads D.M. Engelmann

IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial

Paul M. Ridker, Matt Devalaraja, Florian M.M. Baeres et al. · The Lancet · 2021 · 596 citations

Inflammation, Anti-inflammatory, Cardiovascular Disease +10

Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes

Darren K. McGuire, Nikolaus Marx, Sharon L. Mulvagh et al. · New England Journal of Medicine · 2025 · 194 citations

T-lymphocyte subsets in West African children: Impact of age, sex, and season

Ida Maria Lisse, Peter Aaby, H.C. Whittle et al. · The Journal of Pediatrics · 1997 · 128 citations

Maternal Immunization, Autoimmune Disease, Lymphocyte Development +9

Meat Intake and Iron Status in Late Infancy: An Intervention Study

Mads D.M. Engelmann, Brittmarie Sandström, Kim F. Michaelsen · Journal of Pediatric Gastroenterology and Nutrition · 1998 · 124 citations

Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of <scp>SOUL</scp> , a randomized trial

Darren K. McGuire, Rodica Pop‐Busui, John Deanfield et al. · Diabetes Obesity and Metabolism · 2023 · 114 citations · Full text